# Hepion Pharmaceuticals Inc. (HEPA)

Source: https://www.quantisnow.com/company/HEPA
Generated: 2026-11-16T01:41:48.785Z

- Ticker: HEPA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001583771
- Website: hepionpharma.com

## About

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

## Latest HEPA news and filings

- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759522)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759520)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759519)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759518)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759514)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759512)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759511)
- 2026-10-27 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hepion-pharmaceuticals-inc-6759509)
- 2026-10-26 12:01 UTC [Market Insight] [Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest](https://www.quantisnow.com/insight/hepion-pharmaceuticals-receives-fda-feedback-supporting-a-path-to-demonstrating-6757070)
- 2026-10-21 20:57 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-hepion-pharmaceuticals-inc-6753844)
- 2026-10-21 20:30 UTC [SEC Form 3] [SEC Form 3 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-hepion-pharmaceuticals-inc-6753726)
- 2026-10-19 12:01 UTC [Market Insight] [Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication](https://www.quantisnow.com/insight/hepion-pharmaceuticals-receives-positive-fda-response-on-gv104-in-gambling-6750181)
- 2026-10-14 20:15 UTC [SEC Form S-8] [SEC Form S-8 filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-hepion-pharmaceuticals-inc-6746656)
- 2026-10-14 12:01 UTC [Market Insight] [Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update](https://www.quantisnow.com/insight/hepion-pharmaceuticals-completes-acquisition-of-gravitas-life-sciences-and-provides-6745953)
- 2026-10-09 20:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-hepion-pharmaceuticals-inc-6743040)
- 2026-10-02 20:30 UTC [Insider Buy] [Director Fisher Danina bought $10,000 worth of shares (200,000 units at $0.05) (SEC Form 4)](https://www.quantisnow.com/insight/director-fisher-danina-bought-10000-worth-of-shares-200000-units-6734827)
- 2026-10-02 13:25 UTC [SEC Form 8-K] [Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year](https://www.quantisnow.com/insight/hepion-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6733740)
- 2026-09-28 10:30 UTC [SEC Form 8-K] [Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hepion-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-registrants-6727010)
- 2026-09-16 20:18 UTC [SEC Form 3] [New insider Ki Holdings, Ltd. claimed ownership of 10,000,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ki-holdings-ltd-claimed-ownership-of-10000000-shares-6717604)
- 2026-09-15 21:30 UTC [SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-hepion-pharmaceuticals-inc-6716553)
- 2026-09-14 10:30 UTC [SEC Form 4] [SEC Form 4 filed by Executive Chairman Lopriore Vincent S](https://www.quantisnow.com/insight/sec-form-4-filed-by-executive-chairman-lopriore-vincent-s-6713604)
- 2026-09-10 20:30 UTC [SEC Form DEF 14C filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-hepion-pharmaceuticals-inc-6711836)
- 2026-09-10 20:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Purcell Michael J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-purcell-michael-j-6711689)
- 2026-09-08 21:24 UTC [SEC Form 8-K] [Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/hepion-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6708744)
- 2026-08-27 20:30 UTC [SEC Form 8-K] [Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/hepion-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6697321)
- 2026-08-21 20:36 UTC [SEC Form 4] [SEC Form 4 filed by Interim CEO Stetz Gary S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-interim-ceo-stetz-gary-s-6691537)
- 2026-08-21 20:34 UTC [SEC Form 4] [SEC Form 4 filed by Executive Chairman Lopriore Vincent S](https://www.quantisnow.com/insight/sec-form-4-filed-by-executive-chairman-lopriore-vincent-s-6691519)
- 2026-08-21 20:33 UTC [SEC Form 4] [SEC Form 4 filed by VP, Corp. Dev. Lopriore Chase](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-corp-dev-lopriore-chase-6691511)
- 2026-08-21 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Fisher Danina](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fisher-danina-6691499)
- 2026-08-21 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Liddy James Gordon](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-liddy-james-gordon-6691477)
- 2026-08-21 20:29 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Appajosyula Sireesh](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-appajosyula-sireesh-6691474)
- 2026-08-21 20:28 UTC [SEC Form 4] [SEC Form 4 filed by Director Stetz Gary S. Ii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stetz-gary-s-ii-6691446)
- 2026-08-21 10:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Liddy James Gordon](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-liddy-james-gordon-6690697)
- 2026-08-20 20:45 UTC [SEC Form 8-K] [Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/hepion-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6690300)
- 2026-08-20 20:30 UTC [SEC Form SCHEDULE 13D filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-hepion-pharmaceuticals-inc-6690214)
- 2026-08-13 10:58 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-hepion-pharmaceuticals-inc-6679139)
- 2026-08-13 01:43 UTC [Insider Buy] [Director Stetz Gary S. Ii bought $25,000 worth of shares (500,000 units at $0.05) (SEC Form 4)](https://www.quantisnow.com/insight/director-stetz-gary-s-ii-bought-25000-worth-of-shares-6678907)
- 2026-08-13 01:41 UTC [Insider Buy] [Interim CEO Stetz Gary S. bought $100,000 worth of shares (2,000,000 units at $0.05), increasing direct ownership by 160% to 3,250,000 units (SEC Form 4)](https://www.quantisnow.com/insight/interim-ceo-stetz-gary-s-bought-100000-worth-of-shares-6678905)
- 2026-08-13 01:39 UTC [Insider Buy] [Director Purcell Michael J. bought $100,000 worth of shares (2,000,000 units at $0.05), increasing direct ownership by 160% to 3,250,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-purcell-michael-j-bought-100000-worth-of-shares-2000000-6678902)
- 2026-08-13 01:36 UTC [Insider Buy] [Chief Operating Officer Appajosyula Sireesh bought $100,000 worth of shares (2,000,000 units at $0.05), increasing direct ownership by 160% to 3,250,000 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-appajosyula-sireesh-bought-100000-worth-of-shares-6678898)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/HEPA
- Earnings history: https://www.quantisnow.com/earnings/HEPA
- Dividend history: https://www.quantisnow.com/dividends/HEPA
- Insider transactions: https://www.quantisnow.com/insiders/HEPA
- Options chain: https://www.quantisnow.com/options/HEPA
- SEC 8-K filings only: https://www.quantisnow.com/company/HEPA/8-k
- RSS and alerts for HEPA: https://www.quantisnow.com/docs/rss-feeds.md
